PLEASANTON, CA -- (MARKET WIRE) -- March 30, 2007 -- Lipid Sciences, Inc. (NASDAQ: LIPD) Dr. H. Bryan Brewer, Jr., Chief Scientific Director of Lipid Sciences, Inc., concluded from the wide range of presentations at the recent American College of Cardiology (ACC) Meeting in New Orleans that the rationale for HDL being the next, most logical target for the development of treatments for cardiovascular disease continues to exhibit enormous potential. This conclusion is even more compelling in light of the recent, highly publicized failure of the CETP inhibitor, torcetrapib.
